Global biopharmaceutical company with research and commercial operations across oncology and other therapeutic areas.
Independent editorial and sponsored coverage are visibly separated. Sponsored company reports carry a clear commercial-relationship disclosure and remain subject to the same sourcing, byline, date and correction standards as other newsroom reports.
AstraZeneca completed a $2 billion equity investment in Summit while outlining multi-company trials that will study Datroway together with ivonescimab.
Read full report →Send verifiable public material, a factual correction or a news tip to the editorial desk. Submissions are reviewed independently and do not guarantee publication.
